Philadelphia biopharm company partners with Chinese firm to advance cancer therapy
Context Therapeutics, a Philadelphia biopharmaceutical company focused on hormone-driven cancers, is teaming up with a Chinese biotech firm to advance the development of Context's lead new drug candidate.
That experimental therapy, called onapristone ER, is being evaluated in mid-stage clinical testing in patients with certain types of ovarian and endometrial cancers.
Context plans to conduct mid-stage clinical testing of onapristone ER in patients with breast cancer later this year.
Financial…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: John George Source Type: news
More News: Biotechnology | Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | China Health | Endometrial Cancer | Health Management | Hormones | Ovarian Cancer | Ovaries | Pharmaceuticals